PIK3CA and colon carcinoma: A 2021 preclinical in vitro trial conducted by Aslam et al. showed that PIK3CA-mutated colon carcinoma cell lines are especially sensitive to simultaneous treatment with alpelisib and cyclin-dependent kinase 4 and 6 inhibitor ribociclib compared to wild-type cells [100].